SCHEMBL24243733

SCHEMBL24243733

CCN(C)CCc1c[nH]c2ccc(N)cc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.71
HTR1D P28221 10/20 0.55
HTR1A P08908 7/20 0.55
HTR1B P28222 7/20 0.55
HPGD P15428 1/20 0.55
CYP2C19 P33261 1/20 0.55
MPO P05164 2/20 0.53
HTR2C P28335 3/20 0.52
SLC6A4 P31645 1/20 0.52
HTR2B P41595 3/20 0.50
HTR3E A5X5Y0 2/20 0.50
HTR3B O95264 2/20 0.50
HTR1E P28566 2/20 0.50
HTR1F P30939 2/20 0.50
HTR7 P34969 2/20 0.50
HTR3A P46098 2/20 0.50
HTR5A P47898 2/20 0.50
HTR6 P50406 2/20 0.50
HTR4 Q13639 2/20 0.50
HTR3D Q70Z44 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24243732 0.89 HTR2A (0.59) HTR2AHTR1DHTR1AHTR1BMPO
SCHEMBL1121997 0.87 HTR1A (0.68) HTR2AHTR1DHTR1AHTR1BHPGD
Hydrochloric Acid SCHEMBL3869535 0.85 HTR1A (0.67) HTR2AHTR1DHTR1AHTR1BHPGD
Hydrochloric Acid SCHEMBL7970523 0.85 HTR1A (0.67) HTR2AHTR1DHTR1AHTR1BHPGD
SCHEMBL24243715 0.84 HTR2A (0.72) HTR2AHTR1DHTR1AHTR1BMPO
SCHEMBL24243689 0.83 HTR2A (0.72) HTR2AHTR1DHTR1AHTR1BHPGD
SCHEMBL24243690 0.83 HTR2A (0.71) HTR2AHTR1DHTR1AHTR1BMPO
SCHEMBL21846788 0.83 HTR1D (0.77) HTR2AHTR1DHTR1AHTR1BHPGD
SCHEMBL29904441 0.83 HTR2A (1.00) HTR2AHTR1DHTR1AHTR1BMPO
SCHEMBL24243693 0.83 HTR2A (1.00) HTR2AHTR1DHTR1AHTR1BMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220241243-A1 METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. 2022-08-04 US disclosed
US-20220041551-A1 METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2022-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041551-A1 METHODS OF TREATING MOOD DISORDERS GRIN2C, GRIN2A, TPH2 HTR2A 5/4885HTR1D 53/4885HTR1A 23/4885
US-20220241243-A1 METHODS OF TREATING MOOD DISORDERS GRIN2C, GRIN2A, TPH2 HTR2A 5/4885HTR1D 53/4885HTR1A 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.